In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes

References

• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G. 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• BURKE, M. D., THOMPSON, S., WEAVER, R. J., WOLF, C. R. and MAYER, R. T., 1994, Cytochrome P450 specificities of alkoxyresorufin 0-dealkylation in human and rat liver. Biochemical Pharmacology, 48, 923–936.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1997, Microtiter plate assays for inhibition of human, drug-metabolizing cytochrome P450. Analytical Chemistry, 248, 188–190.
   Google Scholar
• DOMANSKI, T. L., HE, Y.-Q., HARLOW, G. R. and HALPERT, J. R., 2000, Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. Journal of Pharmacology and Experimental Therapeutics, 293, 585–591.
   Google Scholar
• DOOSTDAR, H., GRANT, M. H., MELVIN, W. T., WORE, C. R. and BURKE, M. D., 1993, The effect of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HepG2 hepatoma cells. Biochemical Pharmacology, 46, 629–635.
   PubMed Web of Science ®Google Scholar
• EMOTO, C., YAMAZAKI, H., IKETAKI, H., YAMASAKI, S., SATOH, T., SHIMIZU, R., SUZUKI, S., SHIMADA, N., NAKAJIMA, M. and Yoxoi, T., 2001, Cooperativity of a-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica, 31, 265–275.
   PubMed Web of Science ®Google Scholar
• GERVOT, L., ROCHART, B., GAUTIER, J. C., BOHNENSTENGEL, F., KROEMER, H., DE BERARDINIS, V., MARTIN, H., BEAUNE, P. and DE WAZIERS, I., 1999, Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics, 9, 295–306.
   PubMedGoogle Scholar
• GONZALES, F. J., 1990, Molecular genetics of the P-450 superfamily. Pharmacology and Therapeutics, 45, 1–38.
   PubMedGoogle Scholar
• GUENGERICH, F. P., 1992, Characterization of human cytochrome P450 enzymes. FASEB Journal, 6, 745–748.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1999, Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39,1–17.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., BRIAN, W. R., IWASAKI, M., SARI, M. A., BAARNHIERM, C. and BERNTSSON, P., 1991, Oxidation of dihydropyridine calcium-channel blockers and analogues by human liver cytochrome P450 3A4. Journal of Medicinal Chemistry, 34, 1838–1844.
   PubMed Web of Science ®Google Scholar
• HANNA, I. H., REED, J. R., GUENGERICH, F. P. and HOLLENBERG, P. F., 2000, Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Archives of Biochemistry and Biophysics, 376, 206–216. "
   Google Scholar
• HOLLENBERG, P. F., 2002, Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metabolism Reviews, 34, 17–35.
   PubMed Web of Science ®Google Scholar
• KATOH, M., NAKAJIMA, M., SHIMADA, N., YAMAZAKI, N. and YOKOI, T., 2000, Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug—drug interactions. European Journal of Clinical Pharmacology, 55, 843–852.
   PubMed Web of Science ®Google Scholar
• KENWORTHY, K. E., BLOOMER, J. C., CLARKE, S. E. and HOUSTON, J. B., 1999, CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48, 716–727.
   PubMed Web of Science ®Google Scholar
• KORZEKWA, K. R., KRISHNAMACHARRY, N., SHOU, M., OGAI, A., PARISE, R. A., RETTIE, A. E., GONZALEZ, F. J. and TRACY, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137–4147.
   PubMed Web of Science ®Google Scholar
• LASKER, J. M., HUANG, M.-T. and CONNEY, A. H., 1984, In vitro and in vivo activation of oxidative drug metabolism by flavonoids. Journal of Pharmacology and Experimental Therapeutics, 229, 162–170.
   Google Scholar
• LUDWIG, E., SCHMID, J., BESCHKE, K. and EBNER, T., 1999, Activation of human cytochrome P-450 3A4-catalysed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. Journal of Pharmacology and Experimental Therapeutics, 290, 1–8.
   PubMed Web of Science ®Google Scholar
• MURRAY, B. P., EDWARDS, R. J., MURRAY, S., SINGLETON, A. M., DAVIES, D. S. and BOOBIS, A. R., 1993, Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis, 14, 585–592.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• NGUI, J. S., TANG, W., STEARNS, R. A., SHOU, M., MILLER, R. R., ZHANG, Y., LIN, J. H. and BAILLIE, T. A., 2000, Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metabolism and Disposition, 28, 1043–1050.
   PubMed Web of Science ®Google Scholar
• NIWA, T., YABUSAKI, Y., HONMA, K., MATSUO, N., TATSUTA, K., ISHIBASHI, F. and RATAGIRI, M., 1998, Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica, 28, 539–547.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• OTTON, S. V., CREWE, H. K., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1988, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 247, 242–247.
   PubMed Web of Science ®Google Scholar
• RENDIC, S., 2002, Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews, 34, 83–448.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding to two substrates in a cytochrome P450 active site. Biochemistry, 33, 6450–6455.
   PubMed Web of Science ®Google Scholar
• SMITH, D. A., ABEL, S. M., HYLAND, R. and JONES, B. C., 1998a, Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica, 28, 1095–1128.
   PubMed Web of Science ®Google Scholar
• SMITH, G., STUBBINS, M. J., HARRIES, L. W. and WOLF, C. R., 1998b, Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica, 28, 1129–1165.
   PubMed Web of Science ®Google Scholar
• STRESSER, D. M., BLANCHARD, A. P., TURNER, S. D., ERVE, J. C. L., DANDENEAU, A. A., MILLER, V. P. and CRESPI, C. L., 2000, Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metabolism and Disposition, 28, 1440–1448.
   Google Scholar
• TANG, W., STEARNS, R. A., KWEI, G. Y., ILIFF, S. A., MILLER, R. R., EGAN, M. A., Yu, N. X., DEAN, D.C., KumAR, S., Suou, M., LIN, J. H. and BAILLIE, T. A., 1999, Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. Journal of Pharmacology and Experimental Therapeutics, 291, 1068–1074.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Coopetativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
   PubMed Web of Science ®Google Scholar
• UMEHARA, K., SHIMOKAWA, Y. and MIYAMOTO, G., 2002, Effect of probucol on cytochrome P450 activities in human liver microsomes. Biological and Pharmaceutical Bulletin, 25, 1112–1114.
   PubMedGoogle Scholar
• WANG, R. W., NEWTON, D. J., Liu, N., ATKINS, W. M. and Lu, A. Y. H., 2000, Human cytochrome P-450 3A4: in vitro drug—drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition, 28, 360–366.
   PubMed Web of Science ®Google Scholar
• WAXMAN, D. J., LAPENSON, D. P., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and KORZEKWA, K., 1991, Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives of Biochemistry and Biophysics, 290, 160–166.
   PubMed Web of Science ®Google Scholar
• WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1999, A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in cynomolgus monkey (Macaca fascicularis) and man. Xenobiotica, 29, 467–482.
   PubMed Web of Science ®Google Scholar
• YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. and UNO, T., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics, 4, 879–885.
   PubMedGoogle Scholar